子宫内膜癌中TROP2、FRα与HER2的整合表达谱分析
单机构回顾性组织芯片研究纳入312例子宫内膜癌(158例子宫内膜样、154例浆液性),分析TROP2、HER2与FRα在不同组织学、分子及基因组亚组中的表达。结果显示TROP2广泛表达,而HER2与FRα阳性集中于浆液性、FIGO 3级及p53异常肿瘤,支持基于生物标志物的ADC开发。
要点
- TROP2在子宫内膜样与浆液性癌中均广泛表达,中位H-score分别为280与200。
- HER2胃评分2+/3+与FRα阳性富集于浆液性癌、FIGO 3级及p53异常肿瘤。
- TROP2/HER2/FRα三阴性肿瘤少见,仅6/308(1.9%)。
核心结论
- TROP2在子宫内膜癌中广泛表达,HER2与FRα则界定出较局限的高级别、浆液性/浆液样、p53异常亚群,支持基于生物标志物的ADC开发。
研究设计与样本
- 单机构回顾性组织芯片研究,纳入312例子宫内膜癌,其中子宫内膜样158例、浆液性154例。
- TROP2采用组织化学评分(H-score)定量;HER2采用子宫内膜癌专用标准及胃/DESTINY-PanTumor02标准评估。
- FRα阳性定义为≥75%存活肿瘤细胞且≥2+膜染色。
- 分子分型采用POLE突变、MSI/MMRd、p53异常与NSMP的层级分类器。
- 分析TMB及复发性基因组改变与生物标志物表达的关系。
主要发现
- TROP2广泛表达,子宫内膜样癌中位H-score为280,浆液性癌为200。
- HER2胃评分2+/3+在浆液性癌与子宫内膜样癌中分别为22.5%与8.9%,FRα阳性分别为20.1%与4.4%。
- HER2 2+/3+与FRα阳性均局限于FIGO 3级肿瘤,并集中于p53异常疾病。
- FRα阳性在POLE突变与MSI/MMRd肿瘤中均缺失。
- HER2 2+/3+与ERBB2改变相关;FRα阳性肿瘤富集TP53改变,ARID1A与PTEN改变频率较低。
关键数值与推荐
- FRα阳性阈值:≥75%存活肿瘤细胞且≥2+膜染色。
- HER2采用子宫内膜癌专用标准与胃/DESTINY-PanTumor02标准评估。
- 分子分型层级:POLE突变、MSI/MMRd、p53异常、NSMP。
临床怎么用
- 对高级别、浆液性/浆液样及p53异常子宫内膜癌可考虑检测HER2与FRα以指导ADC选择。
- TROP2表达广泛,可能覆盖更广的患者人群,但仍需结合分子分型评估。
- FRα阴性见于POLE突变与MSI/MMRd肿瘤,提示该亚群不宜优先考虑FRα靶向治疗。
局限性
- 单机构回顾性组织芯片研究,样本来源与检测方法可能影响外推性。
- 生物标志物表达与治疗反应及临床结局的关联未在本文中报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Antibody-drug conjugates (ADCs) are expanding treatment options in endometrial carcinoma, but the distribution of actionable surface targets across histologic, molecular, and genomic subgroups remains incompletely defined. METHODS: This single-institution retrospective tissue microarray (TMA) study included 312 endometrial carcinomas: 158 endometrioid and 154 serous tumors. Trophoblast cell-surface antigen 2 (TROP2) was quantified by histochemical score (H-score); human epidermal growth factor receptor 2 (HER2) was assessed using endometrial carcinoma-specific and gastric/DESTINY-PanTumor02 criteria; and folate receptor alpha (FRα) positivity was defined as ≥75% viable tumor cells with ≥2+ membranous staining. Molecular class was assigned using a hierarchical DNA polymerase epsilon (POLE)-mutant, microsatellite instability/mismatch repair-deficient (MSI/MMRd), p53-abnormal, and no specific molecular profile (NSMP) classifier. Tumor mutational burden (TMB) and recurrent genomic alterations were analyzed in relation to biomarker expression. RESULTS: TROP2 was broadly expressed, with median H-scores of 280 in endometrioid and 200 in serous carcinomas. HER2 gastric-score 2+/3+ expression and FRα positivity were enriched in serous versus endometrioid carcinoma (22.5% vs 8.9% and 20.1% vs 4.4%), restricted to FIGO grade 3 tumors, and concentrated in p53-abnormal disease. FRα positivity was absent in POLE-mutant and MSI/MMRd tumors. HER2 2+/3+ expression correlated with erb-b2 receptor tyrosine kinase 2 (ERBB2) alterations, whereas FRα-positive tumors were enriched for TP53 alterations and showed lower frequencies of ARID1A and PTEN alterations. Triple-negative TROP2/HER2/FRα tumors were uncommon (6/308, 1.9%). CONCLUSIONS: TROP2 is broadly expressed in endometrial carcinoma, whereas HER2 and FRα define a more restricted high-grade, serous/serous-like, p53-abnormal compartment, supporting biomarker-informed ADC development.
引用
- De Tommasi O, Palmieri L, Bellone S, et al. Integrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FRα), and human epidermal growth factor receptor 2 (HER2) in endometrial Cancer across molecular classes, genomic alterations, and histologic subtypes. Gynecol Oncol. 2026. PMID: 42567118. doi:10.1016/j.ygyno.2026.08.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。